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Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances 
EGFR Signaling and Cetuximab resistance 
 
Hsin-Wei Liao, B.S., M.S. 
Advisory Professor: Mien-Chie Hung, Ph.D. 
 
Protein modifications of epidermal growth factor receptor (EGFR) intracellular 
domain are well known regulators of EGFR functions whereas those of its extracellular 
domain remain relatively unexplored. Here, we report that methylation at R198 and R200 
of EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) 
upregulates its binding to EGF and subsequent receptor dimerization and signaling 
activation. Methylation-defective EGFR mutant reduced tumor growth in mouse 
orthotopic xenograft model. Importantly, increased EGFR methylation sustains its 
signaling activation and cell proliferation in the presence of therapeutic EGFR 
monoclonal antibody, cetuximab. EGFR methylation level also correlates with higher 
recurrence rate after cetuximab treatment and poorer overall survival in colorectal cancer 
patients. These data suggest that R198/R200 methylation plays important role in 
regulating EGFR functionality and resistance to cetuximab treatment. 
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CHAPTER 1. INTRODUCTION 
1.1  Colorectal cancer and epidermal growth factor receptor (EGFR) target therapy 
Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United 
States. The recommended treatment for early stage colorectal cancer is surgical removal, 
while the management of late stage colorectal cancer relies heavily on chemotherapy (1). 
Optimization of dosing and scheduling of chemotherapy agents have been developed to 
improve response and survival rate of patients. Meanwhile, rational targeting of 
molecular signaling pathways that are involved in the etiology of malignancies is 
currently one of the most promising strategies in novel anticancer drug development. The 
comprehensive molecular characterization of 224 CRC cases reported by Cancer Genome 
Atlas Network showed sixteen percent of them are hyper-mutated (2). WNT pathway 
alterations have been found in 93% of all tumors and involved 16 different genes in WNT 
signaling pathway. Tumor growth factor β signaling alterations are identified 
preferentially in the hyper-mutated tumors (87%). Moreover, ERBB family gene 
amplification or mutations are observed in 19% of tumors. Over all, 24 genes are 
significantly mutated and many of them are considered targetable.  
Since the discovery of EGFR in 1962, members of the EGFR family and their 
downstream signals have become one of the most well characterized receptor tyrosine 
kinase (RTK) system. In addition to their function in normal development, aberrant 
expression of EGFR is involved in abnormal cell proliferation (3), reduced apoptosis (4), 
cell migration (5, 6), metastasis (7, 8), and angiogenesis (9) in cancer patients. Owing to 
the importance of EGFR’s role in tumorigenesis, new classes of drugs that target EGFR 
are among the most clinically advanced molecular-targeted therapies. Although EGFR 
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tyrosine kinase inhibitors combined with chemotherapy presented severe toxicity (10-12) 
and limited effects (13, 14), the combination of EGFR monoclonal antibody, such as 
cetuximab and panitumumab, with chemotherapy has shown efficacy in colorectal cancer 
treatment (15, 16).  
Cetuximab was initially approved based on the BOND clinical trial, which 
compared cetuximab plus irinotecan with cetuximab alone in patients with 
fluoropyrimidine- and irinotecan resistant metastatic colorectal cancer (mCRC) (17). 
Response rate and progression free survival for the combination arm are significantly 
more effective than cetuximab only. Subsequently, the NCI-CO17 (Cetuximab and Best 
Supportive Care Compared With Best Supportive Care Alone in Treating Patients With 
Metastatic EGFR-Positive Colorectal Cancer) study confirmed an advantage for 
cetuximab in chemotherapy-resistant mCRC (18). Unfortunately, resistance to EGFR-
targeted therapy has been recently observed, and many potential mechanisms have been 
proposed to explain the poor response to cetuximab, including activation of Her2 (19) or 
MET (20) signaling, mutation of PIK3CA (21) and BRAF (22), or status of PTEN (23) 
However, retrospective analyses revealed inconsistent and controversial findings (24). So 
far, the most accepted predictive marker for poor cetuximab response is mutant KRAS 
status due to it association with poor survival rate under cetuximab treatment in 
colorectal cancer clinical trials (25-28). Therefore, American Society of Clinical 
Oncology has recommended that all patients with metastatic colorectal carcinoma who 
are candidates for therapy with anti-EGFR antibodies should have their tumor tested for 
KRAS mutations, and only patients with wild-type (WT) KRAS are recommended for the 
cetuximab treatment (29). The predictive value of KRAS mutation status for benefit from 
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anti-EGFR monoclonal antibody therapy was similarly confirmed in the trial of 
panitumumab antibody therapy (30). In addition, panitumumab is as effective as 
cetuximab in a phase III clinical trial in patients with chemotherapy-resistant KRAS-wt 
mCRC. Nevertheless, KRAS mutation examination is limited to exon 2 codons 12 and 13 
(31). Around 37% to 45% of CRCs carry activating KRAS mutations in exon 2 (32-35). 
The predictive value of individual exon 2 KRAS-mutation in mCRC is controversial. 
Although some reports have suggested a possible benefit from anti-EGFR monoclonal 
antibody therapy for patients with KRAS codon 13 (G13D) mutations (36, 37), a meta-
analysis of three randomized phase III clinical trials of panitumumab in first-line, second-
line, and refractory settings failed to confirm these findings (38). The observation that 
WT KRAS is not sufficient to confer sensitivity to cetuximab (39-41), while some 
patients with mutant KRAS are still sensitive to cetuximab (24, 36, 37, 42, 43), indicating 
the underlying mechanism of cetuximab resistance remains controversial and warrants 
further investigation to identify potential predictor of cetuximab response. 
Over the last two decades, significant progress has been made in the treatment of 
mCRC. Overall survival has increased from approximately 12 months to nearly 30 
months when treated with fluoropyrimidine monotherapy in recent clinical trials, 
especially in RAS wild type patients (22, 44). More importantly, a better understanding 
regarding molecular mechanism of CRC has largely improved patient prognostication 
and the launch of precision medicine in the treatment of mCRC. In the future, 
development of novel therapeutics for patients with RAS mutations or other defined 
molecular subgroups such as HER2 amplification, PIK3CA, BRAF mutations, would be 
important to improve treatment efficiency. In addition, to understand and overcome the 
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cause of resistance to anti-EGFR therapy in the patients with wild type RAS and wild 
type BRAF will further maximize the therapeutic benefit. 
1.2  Epidermal Growth factor receptor and its regulation 
EGFR family, which includes four members, EGFR, ErbB2/HER2, ErbB3/HER3, 
and ErbB4/HER4, is one of the most well characterized receptor tyrosine kinase systems. 
Members in EGFR family are known oncogenic drivers in lung cancer, breast cancer, 
colorectal cancer and glioblastoma (45-47). EGFR, encoded within the 7p11.2 
chromosomal locus, is the first receptor discovered with intracellular tyrosine kinase 
activity (48). The protein products are expressed in two isoforms of 145 and 165 kD, 
containing the extracellular (EC), transmembrane (TM), intracellular tyrosine kinase 
(TK), and intracellular C-terminal domains.  
Seven activating ligands were identified to regulate activity of EGFR (49), 
including EGF, transforming growth factor α (TGF-α), betacellulin (BTC), heparin-
binding EGF-like growth factor (HB-EGF), amphiregulin (ARG), epiregulin (EPR), and 
epigen (EGN). All these ligands contain an EGF-like domain, with six spatially 
conserved cysteines (that form three intramolecular disulfides), which is responsible for 
receptor binding and activation. The membrane-bound precursor EGFR ligands are 
cleaved by cell-surface proteases in a ligand-specific manner to generate the active 
growth factors (50). Although deficiency of EGFR affect a wide range of cellular 
processes, it still remains unclear which ligands are responsible in which context. Upon 
ligand stimulation, EGFR converts from an inactive monomeric form to an active 
homodimer or to a heterodimer with another EGFR family member. EGFR dimerization 
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leads to a conformational change that triggers autophosphorylation of C-terminal tyrosine 
residues and activates the TK domain. The interaction between EGFR-phosphorylated 
tyrosines and several intracellular proteins with phosphotyrosine binding SH2 domains 
converys signal transduction (51). The downstream signaling pathways include 
phospholipase C (PLC), the signal transducer and activator transcription (STAT), 
phosphatidylinositol 3-kinase (PI3K/Akt), the mitogen-activated protein kinase (MAPK), 
and the SRC/FAK pathways (52). 
Protein modifications play critical roles in regulating stability, localization, 
signaling activation of EGFR. Cross talk between phosphorylation and PRMT5 (protein 
arginine methyltransferase 5)-mediated methylation on intracellular domain regulates 
downstream signaling activation (53), whereas ubiquitination by Cbl mediates EGFR 
stability, trafficking and signal sustainability (54). In addition, EGFR acetylation 
enhances EGFR tyrosine phosphorylation and augmented its association with Src kinase. 
Acetylation-deficient EGFR mutant significantly reduces the activation of EGFR (55). 
While intracellular domain modifications of transmembrane proteins have been well 
studied, only a few types of extracellular domain modifications have been identified (56, 
57). There is evidence that extracellular modifications of transmembrane proteins have 
important physiological functions. For example, extracellular domain phosphorylation of 
cadherin protein by intracellular Golgi kinase or ectokinase regulates cell adhesion, cell 
growth, and cell polarity (57, 58). In addition, glycosylation on the extracellular domain 
of RTK is critical for protein stabilization and subcellular localization (56, 59). However, 
other types of extracellular domain protein modifications besides phosphorylation and 
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glycosylation are still significantly unexplored. Interestingly, our mass spectrum analysis 
revealed several methylated arginines on EGFR extracellular domain. 
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1.3  Protein arginine methylation 
Since the discovery of protein arginine methyltransferases (PRMTs), arginine 
methylation has been implicated in many biological processes and human diseases (60). 
During arginine methylation, PRMTs transfer methyl groups from S-adenosylmethionine 
(SAM) to the guanidine nitrogen of specific arginine residues on their target proteins, 
which in turn alter the protein structure (61), protein-protein interaction (62), protein 
localization (63) and enzyme activity (64) that are critical for various cellular functions. 
For example, signal transduction (65), RNA processing (66), DNA repair (64), and gene 
transcription (67), are regulated by arginine methylation. PRMT1 is the best 
characterized among the ten mammalian PRMT family members, catalyzes around 85% 
of all asymmetric arginine di-methylation events in mammalian cells (68), and is required 
for mammalian development and survival as PRMT1 null mice die around embryonic day 
6.5. However, PRMT1 is dispensable for basic cellular processes such as gene expression 
and DNA replication, because embryonic stem cells are viable under cell culture 
conditions (69). Embryonic fibroblasts from PRMT1-deficient mice have higher 
incidence of chromosome losses, gains, polyploidy, and failure to divide, indicating that 
PRMT1 is essential for cell proliferation and survival (70).  
The methyltransferase activity of PRMT1 toward different substrates is 
modulated by its interactions with TIS21 (tetradecanoyl phorbol acetate-
inducible sequence 21) and BTG1 (B-cell translocation gene 1) (71). In addition, 
interaction between transcriptional regulator hCAF1 (CCR4-associated factor 1) and 
PRMT1 down-regulates the methylation levels of PRMT1 substrates, Sam68 (the Src-
Associated substrate in Mitosis of 68 kDa) and histone H4 (72). In line with the 
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observation that PRMT1 exists in a high molecular weight complex in mammalian cells 
(73), dimerization of PRMT1 is required for its binding to the methyl donor S-adenosyl 
methionine (SAM) (74). Therefore, macromolecular complex formation of PRMT1 is 
critical for the regulation of its enzymatic activity and substrate specificity. Although 
PRMT1 frequently methylates arginine residues in the glycine- and argininerich (GAR) 
motifs or RXR sequences (75), arginine methylation of some PRMT1 substrates do not 
have these motifs. Identification and analysis of more methyl group acceptors will further 
elucidate critical elements of substrate recognition. 
More recently, PRMT1 has been linked to cancers (76-78). For instance, in 
prostate cancer, H4R3 methylation by PRMT1 predicts the risk of cancer recurrence (79); 
in mixed lineage leukaemia (MLL), PRMT1 cooperates with MLL-EEN to promote self-
renewal and colony formation ability of primary hematopoietic progenitors (80); in breast 
cancer, PRMT1 methylates estrogen receptor alpha, leading to subsequent activation of 
AKT and cell cycle progression (81). Importantly, overexpression of PRMT1 has been 
observed in tumor tissues of both breast and colorectal cancer (60). PRMT1 is also 
associated with poor clinical outcomes in colorectal cancer patients and has been 
proposed to serve as a predictive marker for patient prognosis (77). Although high 
PRMT1 expression has been shown to correlate with colorectal cancer progression (82), 
its role in colorectal cancer pathophysiology remains obscure.  
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1.4  Rationale 
The observation of EGFR extracellular domain methylation prompts us to ask 
whether this modification affects EGFR functionality and the efficacy of extracellular 
domain-targeted therapeutic monoclonal antibody, cetuximab, in colorectal cancer 
treatment.  To answer these clinically important questions, we first investigated which 
member in protein arginine methyltransferase family was responsible for extracellular 
domain methylation of EGFR.  Second, we examined the effects of EGFR extracellular 
domain methylation on the receptor signal activation. Third, we studied how EGFR 
extracellular domain methylation affected the cellular and patient response to therapeutic 
monoclonal antibody, cetuximab.    
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CHAPTER 2. MATERIAL and METHODS 
2.1  Constructs, reagents, peptides and antibodies. 
EGFR and PRMT1 constructs were prepared as described previously (53). Four 
extracellular domains, juxtamembrane domain, kinase domain, and C-terminal tail of 
EGFR were further subcloned into pGEX vector for the preparation of truncated EGFR 
recombinant proteins. EGFR (R198/200K) mutagenesis was generated using the 
QuickChange Site-Directed Mutagenesis Kit according to the manufacturer’s protocol 
(Stratagene). Epidermal growth factor (EGF; Sigma) was prepared according to the 
manufacturers’ instructions. Unmodified (Ac-QCSGRCRGKSPSD-C), asymmetric di-
methylated (Ac-QCSG(asymmetric dimethyl-R)C(asymmetric dimethyl-R)GKSPSD-C), 
symmetric di-methylated (Ac-QCSG(symmetric dimethyl-R)C(symmetric dimethyl-
R)GKSPSD-C), and mono methylated (Ac-QCSG(mono methyl-R)C(mono methyl-
R)GKSPSD-C) EGFR peptides were chemically synthesized by Lifetein for antibody 
production in mice and dot blot and peptide competition assays. Anti-EGFR antibody 
(06-847, 1:2,000; Millipore) was used to detect full-length EGFR. Antibodies against 
phospho-Tyr 1086 and -Tyr 1148 (Abcam) were used for detection of EGFR activation. 
Antibodies to ERK (1:5,000; Millipore) and phospho-ERK (1:5,000; Cell Signaling) were 
used to detect the EGFR downstream signaling activation. Anti-PRMT1 (Cell Signaling) 
was used to detect PRMT1 level after overexpression or knockdown. Anti-tubulin 
antibody was purchased from Sigma.  
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2.2  Cell culture. 
SKCO1 (KRAS G12V) and SW48 (KRAS wild type) were purchased from 
ATCC. GEO (KRAS G12A) and HT29 (KRAS wild type) cells were kind gifts from Dr. 
Zhen Fan (MD Anderson cancer center). GEO, HT29, and SW48 cells were cultured in 
DMEM/F-12 with 10% fetal calf serum. SKCO1 cells were cultured in MEM with 10% 
fetal calf serum. All cell lines were characterized as mycoplasma negative and validated 
by STR DNA fingerprinting using the AmpF_STR Identifiler kit according to 
manufacturer's instructions (Applied Biosystems cat 4322288).  The STR profiles were 
compared to known ATCC fingerprints (ATCC.org), and to the Cell Line Integrated 
Molecular Authentication database (CLIMA) version 0.1.200808 
(http://bioinformatics.istge.it/clima/) (Nucleic Acids Research 37:D925-D932 PMCID: 
PMC2686526). The STR profiles matched known DNA fingerprints or were unique. 
Before EGF stimulation, 80% confluent cells were serum-starved for 20 hr, and then 
stimulated with 50 ng/ml EGF for indicated time or 50ng/ml TGFα for 20 min. 
2.3  shRNA construct and transfection 
Lentiviral-based pLKO.1 PRMT1 shRNA vector was obtained from Academia 
Sinica (Taipei, Taiwan). The pLKO.1 scrambled shRNA vector was purchased from 
Addgene. (Cambridge, MA). The PRMT1-targeting shRNA sequences used in the 
lentiviral construct were: 5’-CCGGCCGGCAGTACAAAGACTACAACTCGAGTTGT 
AGTCTTTGTACTGCCGGTTTTTG-3’ (shRNA #1) and 5’-CCGGGCAAGTGAA 
GCGGAATGACTACTCGAGTAGTCATTCCGCTTCACTTGCTTTTTG-3’ (shRNA 
#2). For lentiviral production, PLKO.1 PRMT1 shRNA vector, packaging (pCMV-dr8.Z 
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dvpr) and envelope (pCMV-VSV-G) plasmids were co-transfected into 293T cells using 
Lipofectamine Reagent (Invitrogen, Carlsbad, California). After 48-hr transfection, colon 
cancer cells were infected with viral particles. Stable knockdown clones were selected by 
culturing cells in medium with 4 µg/ml puromycin for 1 month. 
2.4  Mass spectrometry 
EGFR was isolated by immunoprecipitation with anti-EGFR antibody and then 
was analyzed by SDS-PAGE. The protein band corresponding to EGFR was excised and 
subjected to in-gel digestion with trypsin. After isolation by immobilized metal affinity 
chromatography, the enriched methyl-peptides were analyzed by micro-liquid 
chromatography/tandem MS. 
2.5  In vitro methylation assay 
GST-tagged PRMT1 and GST-tagged EGFR fragments were expressed in E. coli 
individually and purified using glutathione sepharose 4B. They were then incubated 
together in the presence of 2.2 Ci S-adenosyl-L-[methyl-3H] methionine (85 Ci/mmol 
from a 0.55 mCi/ml stock solution; MP Biomedicals) for 1 hr at 30 °C in a final volume 
of 50 µl of phosphate-buffered saline. After incubation, samples were separated by SDS-
PAGE and transferred to PVDF membrane. Methylation levels were examined by 
fluorography.  
2.6  In vivo protein interaction by Duolink assay 
Cells were seeded in 8-well chamber slides. When harvesting cells, cells were 
washed with cold PBS twice and fixed with 4% paraformadehyde at 4°C for 2 hr. After 
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two more PBS washes, cells were permeabilized by cold 0.2% Triton X-100 for 30 min at 
room temperature and subjected to Doulink assay (Olink Bioscience) according to the 
manufacturers’ instructions. 
2.7  Cell proliferation assay 
Cells were seeded in 6-well plates (triplicate), and fresh medium (with or without 
gefitinib or cetuximab) were added every day. Cells were then trypsinized and cell 
numbers counted on a daily basis.  
2.8  Anchorage-independent growth assay for colony formation 
The base layer of cell growth matrix containing DMEM/F12 medium, 10% FBS, 
and 0.5% agar was paved in 6-well plates (1.5 ml per well). After solidification of the 
base layer, the top layer (1.5 ml per well) containing DMEM/F12 medium, 10% FBS, and 
0.35% agarose, and cells was plated. Culture medium (1 ml) was added to each well and 
changed every 3 days. After 4-week culture, colonies were stained by 0.005% crystal 
violet. Colonies with a diameter larger than 0.5 mm were counted.   
2.9  Dimerization assay 
Cells were starved in serum free medium for 24 hr. After starvation, cold PBS 
containing 50 ng/ml EGF was added onto plates for 30 min at 4°C. Then, cells were 
washed with cold PBS (137 mM NaCl, 0.67 mM KCl, 8 mM Na2HPO4, 1.4 mM KH2PO4) 
three times and incubated for 2 hr at 4°C with 5 mM cross linker BS3 
(bis[sulfosuccinimidyl] suberate; Thermo scientific) in PBS. After washing three times 
with cold PBS, cross linking reactions were stopped by incubating cells in 50 mM Tris 
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buffer (pH 7.5) for 15 min at ambient temperature. Cells were subsequently lysed and cell 
lysates analyzed by Western blotting. 
2.10  Orthotopic colon cancer mouse model 
All animal experiments were carried out in accordance with approved protocol 
from Institutional Animal Care and Use Committee (IACUC) at MD Anderson Cancer 
Center. Nude female mice at 4-5 weeks of age were maintained at the MD Anderson 
Animal Facility for 1 week prior to injection of cancer cells. The cecum was exteriorized 
through a small midline laparotomy and 107 GEO cells expressing WT EGFR, EGFR 
methylation-site mutant, or vector control were injected into the cecal wall. After 
injection, the abdominal wall was closed by wound clips. One month after surgery, 
tumors were harvested and tumor weight measured. 
2.11  Immunohistochemical staining (IHC) 
IHC of methylated EGFR was performed using homemade me-R198/200 
antibody. Colorectal cancer tissue microarrays were purchased from National Cancer 
Institute Cancer Diagnosis Program. Head and neck cancer samples from patients treated 
with cetuximab were collected from Taipei Veterans General Hospital (N = 38) and 
University of Pittsburgh Medical Center (N = 21). Samples were deparaffinized and 
rehydrated. Antigen retrieval was performed by using 0.01 M sodium-citrate buffer (pH 
6.0) in a microwave oven. The sections were treated with 1% hydrogen peroxide in 
methanol for 30 min to block endogenous peroxidase activity. After 1 hr preincubation in 
10% normal serum to prevent nonspecific staining, the samples were incubated with 
primary antibodies at 4°C overnight. The sections were then treated with biotinylated 
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secondary antibody, followed by incubations with avidinbiotin peroxidase complex 
solution for 1 hr at room temperature. Color was developed with the 3-amino-9-
ethylcarbazole solution. Counterstaining was carried out using Mayer's hematoxylin. All 
immunostained slides were scanned on the Automated Cellular Image System III (ACIS 
III) (Dako, Denmark) for quantification by digital image analysis. A total score of protein 
expression was calculated automatically from the percentage of immunopositive cells and 
immunostaining intensity. 
2.12  Statistics 
Statistical analyses were performed using SPSS software. The association 
between the expression level of methyl-EGFR and PRMT1 was analyzed by Spearman’s 
rank correlation test. Survival curves were plotted using Kaplan-Meier method, and log-
rank tests were performed to evaluate prognostic differences between groups for 
categorical variables. For all analyses, two-sided tests of significance were used. A p 
value of < 0.05 was considered statistically significant. 
2.13  Saturation binding assay 
ELISA 96-well plates were captured with 3 µg/ml anti-EGFR antibody (Abcam) 
in 0.2 M sodium phosphate buffer (pH 6.5) at 100 µl/well overnight at room temperature. 
The plates were then rinsed three times with PBS with 0.05% Tween-20 (PBST) and 
blocked with 200 µl/well of 1% BSA solution at 37°C for 2 h. After rinsing three times 
with PBST, 100 µl/well of HT29-RIPA lysates or RIPA buffer only as a negative control 
were added and incubated at 37°C for 1.5 h. The plates were then washed with 400 
µl/well of PBST three times, followed by addition of recombinant human biotin-EGF at a 
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series of diluted concentrations in RIPA buffer. After incubation at 37°C for 1.5 h, wells 
were washed with 400 µl/well of PBST three times, added by 100 µl/well of streptavidin-
conjugated HRP (1:2,000 in blocking buffer), and incubated for 30 min at room 
temperature. The wells were washed again with PBST three times and 100 µl/well of 
TMB as a peroxidase substrate were added and incubated for 30 min at room temperature. 
The reaction was terminated by addition of 50 µl/well of stop solution. The optical 
density was determined at 450 nm, corrected by subtraction of readings at 570 nm, using 
a BioTek Synergy™ Neo multi-mode reader. The dissociation constant (Kd) was 
estimated by the above binding data and then transformed to create a Scatchard plot with 
GraphPad Prism program (version 6; Prism Software Inc., San Diego, USA). 
2.14  Clonogenic assay 
Cells (5,000 per well) were seeded in 24-well plates. Culture medium was 
changed every three days. After 10 days of culturing, cells were washed by cold PBS 
twice and fixed by 4% paraformadehyde for 1 hr. Cells then were stained by 0.005% 
crystal violet at 4°C overnight. After ddH2O wash, colonies with a diameter larger than 
0.5 mm were counted.  
2.15  Study approval 
This study was approved by the IACUC of the University of Texas MD Anderson 
Cancer Center and adhered to NIH guidelines for the use of experimental animals. 
Human colorectal cancer and head and neck cancer tissues with cetuximab treatment 
were obtained under protocols approved by the University of Texas MD Anderson 
Cancer Center IRB. 
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CHAPTER 3. RESULTS 
3.1  PRMT1 methylates EGFR at R198 and R200  
Mass spectrum analysis of immuno-purified endogenous EGFR proteins from 
SKCO1 colorectal cancer cells demonstrated several methylated arginines on the 
extracellular domain of EGFR, including R53, R98, R198, R200, R285 and R497 (Fig. 1-
Fig. 5). Among them, missense mutation of R198 and R285 were reported in colorectal 
adenocarcinoma (TCGA database), and both happen to be located on EGFR extracellular 
domain 2 (D2) (Fig. 6), suggesting functional importance of these arginine residues in 
colorectal cancer biology. To understand whether methylation of EGFR extracellular 
domain arginines affect its function, we began by first interrogating which protein in 
PRMT family (PRMT1-8) is responsible for methylation of these arginines. Results from 
in vitro methylation screening assay by using D2 as substrate revealed that only PRMT1 
generated strong methylation signal when co-incubated with D2 (Fig. 7). Notably, among 
various functional domains of EGFR (Fig. 6), PRMT1 methylated only extracellular 
domain 2 (D2) (Fig. 7). Next, we individually mutated all three arginines, which were 
positive for methylation as determined by mass spectrum analysis, on D2 to lysine to 
determine which of these are methylated by PRMT1. Mutation of both R198 and R200 
but not R285 to lysine reduced methylation signals compared with wild type EGFR (WT) 
as demonstrated by an in vitro methylation assay (Fig. 8). Methylation signal was 
completely abolished for the R198/200K double mutant, suggesting that these two 
arginines in D2 are the major targets of PRMT1-mediated EGFR methylation in vitro 
(Fig. 9). PRMT1 frequently methylates arginine residues found within glycine-arginine 
rich (GAR) domains (83, 84) and generates asymmetric dimethylated arginine. Sequence 
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alignment between the GAR domains of known PRMT1 substrates and D2 of EGFR 
revealed a putative GAR domain between amino acids 196 and 204 with two arginine 
residues, R198 and R200 (Fig. 10), supporting our observation that R198/200 are the 
target sites of PRMT1 in vitro.  
  
  
Figure 1. Methylation on EGFR 
Mass spectrum analysis showing R53 methylation on immunopurified endogenous EGFR.
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extracellular domain Arg53. 
 
 
 
  
 
Figure 2. Methylation on EGFR extracellular domain
Mass spectrum analysis showing R98 methylation on 
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 Arg98. 
immunopurified endogenous EGFR.
 
 
 
  
Figure 3. Methylation on EGFR extracellular domain
Mass spectrum analysis showing R198 and R200 methylation on immunopurified 
endogenous EGFR. 
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 Arg198 and Arg200
 
 
. 
  
Figure 4. Methylation on EGFR extracellular domain
Mass spectrum analysis showing R285 methylation on immunopurified endogenous 
EGFR. 
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 Arg285. 
 
 
  
Figure 5. Methylation on EGFR extracellular domain
Mass spectrum analysis showing R497 methylation on immunopurified endogenous 
EGFR. 
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 Arg497. 
 
 
  
Figure 6. Illustration of EGFR extracellular and intracellular domains
Illustration of EGFR extracellular and intracellular domains that were individually 
subcloned with GST tag and were purified for 
 
 
 
 
 
34 
. 
in vitro methylation assay.  
 
 
  
Figure 7. In vitro methylation assay
In vitro methylation assay showing methylation signal from each GST
domain after incubation with purified GST
examined by fluorography.  
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Figure 8. In vitro methylation assay of WT EGFR and methyla
mutants.  
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Figure 9. In vitro methylation assay of WT EGFR and R198/200K double mutant. 
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Figure 10. Sequence alignment of PRMT1 substrates along with EGFR 
potential GAR motif on EGFR extracellular domain 2.
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3.2  PRMT1 interacts with and methylates EGFR before its translocation to the cell 
membrane 
To analyze the methylation status of endogenous EGFR, we generated an anti-me-
R198/200 methylation-specific antibody by using a synthesized asymmetric dimethylated 
EGFR peptide. Dot blot assay showed that this me-R198/200 antibody recognized 
asymmetric dimethylated R198/200 EGFR peptide but not unmodified R198/200 EGFR 
peptide, other methylation forms of R198/200 EGFR peptide, or asymmetric 
dimethylated histone H4 peptide (Fig. 11), validating the specificity of the antibody. The 
me-R198/200 antibody was later used to detect the methylation level of endogenous 
EGFR. We found that the methylation status of endogenous EGFR was proportional to 
PRMT1 expression, and the methylation signal detected by the me-R198/200 antibody 
was specifically depleted by methylated but not by unmodified peptides (Fig. 12), 
supporting that EGFR R198/200 methylation is regulated by PRMT1 in cells. 
 PRMT1 is an intracellular protein and less likely to contact with R198 and R200, 
which are located on the extracellular domain of EGFR, when EGFR is transported to the 
cell membrane. Protein modifications on the extracellular domain of transmembrane 
proteins, such as phosphorylation and glycosylation can occur during biosynthesis before 
the transmembrane proteins are transported to cell membrane (56, 57, 59). Therefore, we 
speculated that PRMT1 methylates R198/200 through a similar mechanism, before EGFR 
is transported to the cell membrane. To investigate this possibility, we examined 
methylation status by treating cells with or without tunicamycin, an N-linked 
glycosylation inhibitor. During EGFR protein translation and maturation, glycans are 
added onto its extracellular domain before it is transported to the cell membrane. 
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Addition of tunicamycin disrupted glycosylation, resulting in the accumulation and 
retention of immature, unglycosylated EGFR (130 kDa) in the endoplasmic reticulum 
(ER)-Golgi compartments (85). In the presence of tunicamycin, we detected EGFR 
methylation using the me-R198/200 antibody in both newly synthesized (130 kDa) and 
old (170 kDa) EGFR. EGFR methylation signals were reduced when we knocked down 
PRMT1 (Fig. 13, top). To rule out the possibility that PRMT1 methylates EGFR during 
cell lysis, PRMT inhibitor, AMI1, was added into the cell lysis buffer (86). Detection of 
methylation signals both in the presence or absence of AMI1 indicated that the 
methylation event occurred in cells before cell lysis. The efficacy of AMI1 was validated 
by in vitro methylation assay in which the addition of AMI1 blocked methylation 
reaction of PRMT1 toward GST-GAR, a methyl-accepting substrate (Fig. 13, bottom). 
To further validate that newly synthesized EGFR is methylated, we isolated ER organelle 
and showed that the newly synthesized EGFR in the isolated ER was indeed methylated 
as detected by the me-R198/200 antibody (Fig. 14). In contrast, knocking down of 
PRMT1 abolished methylated EGFR signals. Next, we validated the interaction between 
PRMT1 and EGFR by reciprocal co-immunoprecipitation (Fig. 15). Additionally, in vivo 
Duolink assay showed that the PRMT1-EGFR interaction occurred mainly in the 
intracellular space rather than on the cell membrane (Fig. 16). Taken together, the results 
suggest that PRMT1 interacts with and methylates EGFR before its translocation to the 
cell membrane. 
  
  
Figure 11. Dot blot showing specificity
H3R4: Histone H4 arginine 3 asymmetric dimethylated peptide. Asym
peptides asymmetric dimethylat
dimethylated R198/200 peptide. 
Scrambled: peptide with the same amino acid composition as the EGFR R198/200 
peptide with the amino acids scrambled while maintaining the position of the two methyl
arginines.  
 
 
 
41 
 of EGFR me-R198/200 Ab.  
 di
ion on indicated sites. Sym di-me: EGFR symmetric 
Mono-me: EGFR mono methylated R198/200 pe
 
-me: EGFR 
ptide. 
-
 
  
Figure 12. Immunoblots comparing EGFR methylation level in SKCO1 cells
Immunoblots comparing EGFR methylation level in SKCO1 cells exogenously 
expressing PRMT1 (left), PRMT1 shRNA (right), or control vector with EGFR 
methylation-specific antibody, me
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Figure 13. EGFR is methylated before membrane translocation.
Top: Immunoblots of indicated proteins of SKCO1 cells expressing control vector or 
PRMT1 shRNA in the absence or presence of tunicamycin (2 
µM). Bottom: In vitro methylation assay showing methylation signal of GST
incubation with purified GST
µM). Methylation signal were examined by fluorography. 
 
          
 
 
43 
 
µM, 24 hr) or AMI1 (100 
-tagged PRMT1 in the absence or presence of AMI1 (100 
 
 
 
-GAR after 
  
Figure 14. Isolation of ER organelle.
Immunoblots of indicated proteins after ER isolation of SKCO1 cells expressing control 
vector or PRMT1 shRNA.  Calnexin: ER marker; Lamin b1: nuclear marker; HSP60: 
mitochondrial marker.  
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Figure 15. Reciprocal co-immunoprecipitation of
Reciprocal co-immunoprecipitation of SKCO1 cells with the indicated antibodies. 
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 EGFR and PRMT1. 
 
 
 
  
 
Figure 16. Duolink assay of SKCO1 cells. 
Red spots represent the interaction between PRMT1 and EGFR. Phase contrast image 
shows cell boundary. 
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3.3  PRMT1 upregulates EGFR signaling and cell proliferation in colorectal cancer 
cell lines  
Next, we asked how PRMT1 affects EGFR signaling. EGFR activation status was 
evaluated upon EGF stimulation by measuring specific tyrosine phosphorylation and two 
main downstream signaling, ERK and AKT, in both SKCO1 and GEO colorectal cancer 
cells expressing exogenous PRMT1 or vector control. Interestingly, EGFR activation was 
stronger in PRMT1-expressing than in vector control cells upon stimulation by EGF (Fig. 
17 and Fig. 18) and another EGFR ligand, transforming growth factor alpha (TGFα), 
which is also highly expressed in colorectal cancer (87) (Fig. 19). Notably, exogenous 
expression of catalytically inactive mutant PRMT1 did not enhance EGFR activation or 
its downstream signaling, which indicates that upregulation of EGFR signaling by 
PRMT1 requires its enzymatic activity (Fig. 20).  In contrast, knockdown of PRMT1 by 
two different shRNAs severely blocked EGF-induced EGFR, ERK, and AKT activation 
(Fig. 21 and Fig. 22). Although high PRMT1 expression has been shown to correlate with 
colorectal cancer progression (82), its role in colorectal cancer pathophysiology remains 
obscure. We therefore measured cell proliferation and anchorage-independent cell growth 
of stable transfectants that ectopically expressed PRMT1 with or without treatment of 
EGFR tyrosine kinase domain inhibitor, gefitinib. In line with upregulated EGFR 
signaling by PRMT1, gefitinib significantly inhibited cell proliferation (Fig. 23 and Fig. 
24) and anchorage-independent growth (Fig. 25) in both PRMT1-overexpressing and 
vector control (expressing endogenous PRMT1) cells, supporting the concept that 
PRMT1 upregulates EGFR signaling in response to ligand stimulation and increases 
cellular transformation. 
  
Figure 17. PRMT1 upregulates EGFR signaling 
Immunoblots comparing pEGFR, 
indicated time in SKCO1.  
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in SKCO1 cell.  
pERK, and pAKT level upon EGF stimulation for 
 
 
  
Figure 18. PRMT1 upregulates EGFR signaling 
Immunoblots comparing pEGFR, pERK, and pAKT
indicated time in GEO cells expressing PRMT1 or control vector. 
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Figure 19. PRMT1-mediated upregulation of EGFR signaling can be stimulated by 
TGFα.  
Immunoblots comparing pEG
GEO cells expressing PRMT1 or control vector.
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FR and pERK levels upon TGFα stimulation for 20 min in 
  
 
  
Figure 20. PRMT1-mediated upregulation of EGFR signaling is enzymatic activity 
dependent.  
Immunoblots comparing pEGFR and pERK levels upon EGF stimulation for 20 min in 
SKCO1 cells expressing control vector, wild type or catalytically inactive mutant PRMT1.
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Figure 21. Immunoblots of 
Immunoblots evaluating pEGFR, pERK and pAKT level upon EGF stimulation for 
indicated time in SKCO1 cells expressing 
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SKCO1 cells expressing first PRMT1 shRNA.
first PRMT1 shRNAs or control vector. 
 
 
 
 
  
Figure 22. Immunoblots of 
Immunoblots evaluating pEGFR, pERK and pAKT level upon EGF stimulation for 
indicated time in SKCO1 cells expressing 
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SKCO1 cells expressing second PRMT1 shRNA.
second PRMT1 shRNAs or control vector. 
 
 
 
 
  
Figure 23. Cell proliferation assay of SKCO1 cells
Cell proliferation assay of SKCO1 cells expressing PRMT1 or vector control with or 
without gefitinib treatment. P
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 < 0.05, t-test.  
 
 
  
Figure 24. Cell proliferation 
Cell proliferation assay of 
without gefitinib treatment. P
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assay of GEO cells. 
GEO cells expressing PRMT1 or vector control with or 
 < 0.05, t-test.  
 
 
  
Figure 25.  Anchorage-independent growth of SKCO1
Anchorage-independent growth of 1,000 SKCO1 exogenously expressing PRMT1 and 
control vector with or without gefitinib treatment. **
data were generated from a minimum of three replicates. Data are expressed as mean 
±SD. 
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 cells. 
P < 0.005, t-test.  All quantitative 
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3.4  PRMT1 upregulates EGFR dimerization, activation, and EGFR-dependent cell 
proliferation through R198/200 methylation 
To understand whether PRMT1 upregulates EGFR signaling through R198/200 
methylation, we constructed a full-length EGFR R198/200K mutant that cannot be 
methylated by PRMT1 for comparison with WT EGFR. Since both pEGFR and pERK 
were significantly changed by ectopic expression or knockdown of PRMT1 (Fig. 17, 18, 
21 and 22), we used them as markers to monitor EGFR signaling. Notably, EGFR and 
ERK phosphorylation were significantly reduced in GEO cells expressing the R198/200K 
mutant compared with those expressing the WT EGFR, suggesting the importance of 
EGFR R198 and R200 methylation for PRMT1-upregulated EGFR signaling (Fig. 26). 
To further confirm that stronger signaling activation of WT EGFR was a result of 
R198/200 methylation by PRMT1, we knocked down PRMT1 in both WT EGFR and 
EGFR R198/200K expressing HT29 colorectal cancer cells.  Consistently, HT29 cells 
expressing exogenous WT EGFR had stronger EGFR and downstream ERK activation 
than those expressing exogenous EGFR R198/200K mutant (Fig. 27, left). Notably, 
knocking down of PRMT1 reduced signaling activation of exogenous WT EGFR but not 
exogenous EGFR R198/200K mutant (Fig. 27, middle and right). In line with EGFR 
activation, HT29 cells expressing exogenous WT EGFR also had higher cell proliferation 
rate (Fig. 28) compared with EGFR R198/200K-expressing cells. Knocking down of 
PRMT1 in WT EGFR-expressing cells significantly reduced the EGFR-dependent cell 
growth rate to a similar level observed in EGFR R198/200K-expressing cells, indicating 
that PRMT1 upregulates EGFR-dependent cell growth via R198/200 methylation.  
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 R198 and R200 are situated in the hinge region between D1 and D2. Available 
crystallographic structures show that EGFR dynamically transitions between an inactive 
monomeric ‘tethered’ conformation and an active dimeric ‘extended’ conformation (Fig. 
29) (88, 89). In the inactive form, the R198 side chain inserts into a narrow pocket 
provided by D1. Asymmetric dimethylation would increase the volume of R198 
sufficiently to cause unfavorable steric clashes with D1, and hence disfavor the inactive 
conformation (Fig. 30A, left). In the active form, the same binding pocket is substantially 
enlarged (Fig. 30A, right) and provides sufficient space and hydrophobic surface patches 
(green) to accommodate asymmetric dimethylation. The relative orientation of domains 
D1 and D2 is conserved in all dimeric EGFR forms, including ligand-free forms from the 
drosophila EGFR homolog (90, 91), suggesting that our analysis holds for all dimeric 
conformations. Meanwhile, in the inactive form, R200 compensates for the charge of 
D206 (Fig. 30B, left), and the backbone carbonyl of D206 binds to the backbone nitrogen 
of R200. In the active form, the side chain of D206 is rotated away and exposed to the 
solvent. The D206 carbonyl forms a hydrogen bond with R200, bringing the R200 
guanidinium moiety close to the hydrophobic surface of P219 (Fig. 30B, right). 
Consequently, methylation of R200 appears to favor the active conformation, because it 
provides a less charged and more hydrophobic environment for R200. Our structural 
analysis therefore suggests that R198/200 methylation predisposes EGFR to assume an 
active conformation, and hence increases ligand-stimulated downstream signaling, 
supporting the observation of upregulated EGFR signaling and EGFR-dependent cell 
growth by R198/200 methylation.  
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The effect of EGFR R198/200 methylation by PRMT1 on EGFR signaling and 
subsequent cell growth prompted us to investigate how this extracellular modification 
affects intracellular downstream signaling of the receptor. Given that D2 of EGFR is 
critical for the receptor dimerization and subsequent downstream signaling activation 
(92), we further examined the effect of R198/R200 methylation on EGFR dimerization. 
Interestingly, upon EGF stimulation, endogenous EGFR of PRMT1-expressing SKCO1 
cells showed higher receptor dimerization ability than cells expressing control vector (Fig. 
31). In contrast, EGFR in PRMT1 shRNA-expressing cells had lower EGF-stimulated 
dimer formation than cells expressing control vector (Fig. 32). Consistently, loss of 
methylation of EGFR R198/200K mutant significantly reduced its dimerization ability 
compared with WT EGFR in GEO cells (Fig. 33). Knocking down of PRMT1 in WT 
EGFR-expressing cells significantly reduced the dimer formation of WT EGFR to a 
similar level observed in EGFR R198/200K-expressing cells, indicating that PRMT1 
upregulates EGFR dimerization via R198/200 methylation (Fig. 33). Notably, while 
glycosylation was reported to affect the expression level of cell surface EGFR (93), our 
data indicated that methylation did not (Fig. 34). These results support a model that 
methylation at R198/200 of EGFR by PRMT1 enhances its EGF-induced dimerization 
ability and provide an explanation for PRMT1-upregulated EGFR signaling and cell 
proliferation.   
  
  
 
Figure 26. PRMT1 upregulates EGFR 
Immunoblot comparing EGFR and downstream ERK activation level of GEO cells 
expressing control vector, WT and methylation
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activation through R198/200 methylation.
-site mutant EGFR upon EGF stimulation. 
 
 
  
 
  
Figure 27. PRMT1 upregulates EGFR activation through R198/200 methylation
HT29 cells.  
Immunoblot comparing EGFR and downstream ERK activation level of HT29 cells 
expressing control vector, WT and R198/200K mutant EGFR with or without PRMT1 
knocking down upon EGF stimulation. 
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Figure 28. PRMT1 EGFR-dependent cell proliferation through R198/200 
methylation.  
Cell proliferation assay of HT29 cells expressing control vector, WT and R198/200K 
mutant EGFR with or without PRMT
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Figure 29. Structural analysis of EGFR. 
Left: Inactive ‘tethered’ conformation of EGFR. The structure was prepared based on the 
crystal structure of the inactive human EGFR (PDB accession 1IVO)
are color-coded; the weakly bound EGF is in cyan. R198 and R200 are highlighted. Right: 
Active dimerized form of EGFR (based on the crystal structure of human EGFR, PDB 
accession 1NQL). The second EGFR and EGF molecules are shown in gr
respectively.  
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Figure 30. Structural analysis of EGFR Arg 198
Zoom onto R198 (A) and R200 (
EGFR (with the exception of the region 198
atoms; red, negatively charged atoms; green, hydrophobic atoms; salmon, polar oxygens; 
marine, polar nitrogens; yellow
is the location of D206.  
A 
              
B 
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 and Arg 200.  
B) shown as stick figures. The molecular surface of 
-200) is colored in blue, positively charged 
, sulfur). EGFR domains are indicated on the surfaces, as 
 
 
 
  
Figure 31. PRMT1 upregulates EGFR dimerization.
Top: Dimerization assay of SKCO1 cells exogenously 
PRMT1. Anti-EGFR antibody was used to detect EGFR monomer and dimer.
Quantification of  EGFR dimer form.
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expressing vector control and
 
 
 
 
 
 Bottom: 
  
Figure 32. Knocking down of PRMT1 attenuates EGFR dimerization ability.
Top: Dimerization assay of SKCO1 cells expressing vector control
Bottom: Quantification of EGFR dimer form.
 
               
             
 
 
66 
 and PRMT1 shRNA.
 
 
 
 
 
 
  
Figure 33. PRMT1 upregulates EGFR dimerization through R198/200 methylation.
Dimerization assay of GEO cells expressing 
without knocking down of PRMT1
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Figure 34. EGFR methylation does not affect its cell surface expression level.
A and B, Biotinylated cell surface EGFR from 
captured on streptoavidin-agarose beads and detected by immunoblot.
A 
                                  
 
  B 
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3.5  Methylation of EGFR increases tumorigenesis in orthotopic colorectal cancer 
mouse model and correlates with poorer clinical outcomes of colorectal cancer 
patients 
Our current data support a model in which PRMT1 enhances EGFR dimerization 
and activation through methylation of EGFR at R198/200. Subsequently, upregulated 
EGFR signaling promotes cell proliferation and anchorage-independent growth of 
colorectal cancer cells. To further address the pathological relevance of this model, we 
examined whether PRMT1-mediated EGFR methylation contributes to tumorigenesis in 
an orthotopic colon cancer mouse model. One month after injection, HT29 cells 
expressing WT EGFR generated significantly larger tumors than those expressing 
R198/200K EGFR or vector control (Fig. 35). Knocking down PRMT1 substantially 
reduced tumor growth, supporting the positive role of EGFR R198/200 methylation in 
colorectal cancer tumorigenesis. To further address the clinical relevance of EGFR 
R198/200 methylation, we characterized me-R198/200 antibody for its ability to detect 
EGFR R198/200 methylation in immunohistochemical staining (IHC). GEO cells 
expressing WT EGFR, R198/200K EGFR or vector control were fixed on slides by 
cytospin and stained by me-R198/200 antibody. As shown in Fig. 36A, IHC staining 
signals were significantly stronger in WT EGFR expressing cells than R198/200K EGFR 
or vector expressing cells. The staining signals in WT EGFR expressing cells were 
blocked by synthesized asymmetric dimethylated R198/200 EGFR peptide, but not by 
unmodified R198/200 EGFR peptides or asymmetric dimethylated histone H4 peptide, 
validating the specificity of the me-R198/200 antibody. Similarly, me-R198/200 antibody 
was able to detect EGFR methylation signals in patient tissue samples and these 
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methylation signals were blocked specifically by asymmetric dimethylated R198/200 
EGFR peptide, but not by other forms of peptides (Fig. 36B). A retrospective study of 
clinical colorectal cancer specimens further indicated that EGFR R198/200 methylation 
level as detected by me-R198/200 antibody was elevated in tumor tissue compared with 
paired adjacent normal tissue. Also, higher EGFR R198/200 methylation level coincided 
significantly with poorer overall patient survival (Fig. 37) and higher recurrence rate (Fig. 
38). Collectively, these results suggest that PRMT1-mediated EGFR R198/200 
methylation contributes to tumorigenesis in vivo and the methylation status of EGFR has 
the potential to serve as a predictive marker for patient prognosis.  
  
  
Figure 35. Methylation of EGFR increases tumorigenesis in orthotopic colorectal 
cancer mouse model  
In vivo orthotopic colon tumor growth of HT29 ce
(WT), or R198/200K mutant (Mut) EGFR with or without knockdown of PRMT1 (N = 5 
per group). Top: Representative tumors from each group in the fourth week after 
inoculation.  
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Figure 36. Characterization of me
A, Immunochemistry staining of GEO cells expressing WT, R198/200K EGFR or vector 
control by me-R198/200 Ab 
EGFR peptide, asymmetric dimethylated histone H4R3 peptide or asymmetric 
dimethylated R198/200 EGFR peptide. 
tissue by EGFR methylation antibody competed 
A 
 
 
B  
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-R198/200 antibody. 
competed without or with synthesized unmodified R198/200 
B, Immunochemistry staining of colon cancer 
without or with indicated peptide. 
 
 
 
 
  
Figure 37. Methylation of EGFR correlates with poorer 
colorectal cancer patients.  
Kaplan-Meier plot of overall survival of 215 colorectal cancer cases with
methyl-EGFR level detected by me
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Figure 38. Methylation of EGFR correlates with 
cancer patients.  
Kaplan-Meier plot of recurrence rate of 120 colorectal cancer cases with low or high 
methyl-EGFR level detected by me
 
               
 
 
74 
higher recurrence rate 
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3.6  EGFR methylation enhances EGF binding to EGFR and correlates with higher 
recurrence rate of colorectal cancer patients after cetuximab treatment  
Clinically, cetuximab is used to treat metastatic colorectal cancer by disabling the 
interaction between EGF ligand and EGFR and attenuating EGFR signaling (94-96). 
Cetuximab binds exclusively to D3 of EGFR in its inactive conformation (Fig. 29). Upon 
binding, cetuximab occludes the EGF-binding site and prevents EGFR from adopting the 
active conformation required for ligand binding and dimerization (97). By predisposing 
EGFR to assume an active EGF-bound conformation, R198/200 methylation is expected 
to enhance the interaction between EGFR and EGF. Therefore, we asked whether 
R198/200 methylation of EGFR affects its affinity for EGF and the efficacy of cetuximab. 
Dissociation constant (Kd) between EGFR and EGF in the absence or presence of 
cetuximab was measured in the EGFR stable transfectants in HT29 and SW48 colorectal 
cancer cells by saturation binding assay. In the absence of cetuximab, WT EGFR in 
HT29 (Fig. 39) and SW48 (Fig. 40) cells showed higher binding affinity (lower Kd) for 
EGF (Kd = 16.03 nM and Kd = 16.21 nM in HT29 and SW48, respectively) compared 
with the R198/200K mutant EGFR (Kd = 52.16 nM and Kd = 51.79 nM in HT29 and 
SW48, respectively). Knocking down PRMT1 in WT EGFR-expressing HT29 or SW8 
cells significantly reduced the affinity of EGFR for EGF (Kd = 44.32 nM; Kd = 46.65 nM 
in HT29 and SW48, respectively) to a level comparable to that of the R198/200K mutant. 
The binding affinity between the R198/200K mutant EGFR and EGF was not affected by 
PRMT1 knockdown (Kd = 55.09 nM and Kd = 54.54 nM in HT29 and SW48, 
respectively). These results suggest that methylation of EGFR R198/200 by PRMT1 
enhances its binding to EGF. In addition, in the presence of a relatively low concentration 
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of cetuximab (1 µg/ml), at which the binding affinity between WT EGFR and EGF did 
not change significantly compared to the absence of cetuximab (Fig. 41; Kd from 17.86 
to 17.25 nM, without and with cetuximab, respectively), the affinity of R198/200K 
mutant EGFR for EGF was significantly reduced (Kd from 47.28 to 94.33 nM, without 
and with cetuximab, respectively). Together, these results suggest that methylated EGFR 
at R198/200 responds better to EGF binding and is more resistant to cetuximab treatment. 
In line with the higher EGF binding affinity and higher EGFR methylation level, 
PRMT1-overexpressing HT29 cells demonstrated higher EGFR and ERK activation after 
EGF stimulation, and the upregulated pEGFR and pERK remained relatively strong even 
in the presence of cetuximab in comparison to vector control cells (Fig. 42). To validate 
role of EGFR methylation in cetuximab response, cells expressing exogenous PRMT1 
shRNA or PRMT1 were treated with cetuximab, and their clonogenic ability was 
evaluated (Fig. 43-47). The colony number was relatively lower in PRMT1 knocking 
down cells than control cells in the presence of cetuximab (Fig. 43-45). In contrast, cells 
expressing exogenous PRMT1 showed more resistance to cetuximab treatment (Fig. 46 
and Fig. 47). To further investigate whether methyl-EGFR level is related to patient 
response to cetuximab, tumor tissues from cetuximab-treated metastatic colorectal cancer 
patients were collected and stained by me-R198/200 antibody. Consistent with previous 
clinical analyses (15, 17, 98), no association was found between total EGFR expression 
level and cetuximab response (Fig. 48); however, higher levels of methyl-EGFR in 
tumors from colorectal cancer patients correlated with higher recurrence rate after 
cetuximab treatment (Fig. 49). In addition, the expression level of methyl-EGFR 
correlated positively with PRMT1 expression (Fig. 50). Similarly, the correlation 
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between the expression level of methyl-EGFR and PRMT1 was also observed in patients 
with head and neck cancer (Fig. 51), another FDA-approved cancer type for cetuximab 
treatment. Importantly, higher methyl-EGFR level also correlated with poorer overall 
survival after cetuximab treatment in head and neck cancer patients (Fig. 52). Together, 
the results support the notion that PRMT1-mediated EGFR R198/200 methylation 
contributes to cetuximab resistance in colorectal and head and neck cancer patients.  
Clinically, the status of KRAS mutation has been used as a biomarker to predict 
patient response to cetuximab (29), we therefore asked whether methylation-mediated 
cetuximab resistance is affected by KRAS mutation. Interestingly, independently of KRAS 
status, knockdown of PRMT1 in all WT KRAS (HT29 and SW48) (Fig. 43 and Fig. 45) 
and mutant KRAS (SKCO1:  KRAS G12V and GEO: KRAS G12A) (Fig. 53 and Fig. 44) 
cell lines sensitized cells to cetuximab treatment. Notably, knockdown of PRMT1 in 
KRAS G12V mutant and cetuximab-resistant SKCO1 cells rendered cells more sensitive 
to cetuximab than vector control cells; In contrast, re-expression of shRNA-resistant 
PRMT1 (rPRMT1) in PRMT1-knockdown cells restored the observed cetuximab 
resistance (Fig. 53), suggesting that KRAS mutation does not play a role in PRMT1-
mediated cetuximab resistance. 
  
  
Figure 39. EGFR methylation regulates EGF binding to EGFR
Top: Scatchard plot and binding curves (inset) which measured EGFR
affinity of HT29 cells expressing wild type (WT) or R198/200K mutant (Mut) EGFR 
with or without knocking down of PRMT1. Bottom: Bar graph of 
EGFR, Blue: R198/200K mutant EGFR. 
 
                             
               
 
 
78 
.  
-EGF binding 
Kd values, Red: WT 
  
 
 
  
Figure 40. EGFR R198/200 methylation regulates EGF binding to EGFR
Top: Scatchard plot and binding curves (inset) which measured EGFR
affinity of SW48 cells expressing WT or R198/200K mutant EGFR with or without 
knocking down of PRMT1. Bottom: Bar graph of 
R198/200K mutant EGFR.  
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Figure 41. EGFR methylation regulates EGF binding to EGFR after cetuximab 
treatment.  
Top: Scatchard plot and binding curves (inset) which measured EGFR
affinity of HT29 cells expressing
with or without cetuximab treatment. Bottom: Bar graph of 
Blue: R198/200K mutant EGFR.
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Figure 42. EGFR methylation regulates EGF binding to EGFR and correlates with 
higher recurrence rate of colorectal cancer patients after cetuximab treatment.
Immunoblot assessing EGFR, ERK, and AKT activation levels of HT29 cells expressing 
control vector or PRMT1 upon EGF stimulation in the presence or absence of cetuximab. 
 
 
 
81 
 
  
 
 
  
Figure 43. EGFR methylation regulates 
in HT29 cells.  
Clonogenic assay of HT29 cells expressing control vector or PRMT1 shRNA under 
cetuximab treatment (N = 3). Data are expressed as mean ±SD. Expression levels of 
PRMT1 shown by immunoblot. Data shown are representative of at le
experiments.  
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Figure 44. EGFR methylation regulates 
in GEO cells.  
Clonogenic assay of GEO cells expre
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Figure 45. EGFR methylation regulates 
in SW48 cells. 
Clonogenic assay of SW48 cells expre
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Figure 46. EGFR R198/200 methylation increases cetuximab resistance
Clonogenic assay of GEO cells expressing control vector or 
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Figure 47. EGFR R198/200 methylation increases cetuximab resistance
cells.  
Clonogenic assay of  SW48 c
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Figure 48. Correlation betwee
Kaplan-Meier plot of recurrence rate of 41 colorectal cancer cases with wild
treated with cetuximab with low or high total EGFR level.
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Figure 49. Correlation between EGFR methylation level 
colorectal cancer patients. 
Kaplan-Meier plot of recurrence rate of 41 colorectal cancer cases with wild
treated with cetuximab with low or high methyl
Ab. P < 0.05, t-test.    
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Figure 50. Correlation between PRMT1 expression and EGFR methylation level in 
colorectal cancer patients. 
Spearman’s rank correlation test for correlation 
cetuximab-treated wild-type KRAS
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Figure 51. Correlation between PRMT1 expression and EGFR methylation level in 
head and neck cancer patients.
Statistic analysis for expression correlation between methyl
cetuximab-treated head and neck cancer patients.
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Figure 52. Correlation between EGFR methylation level and cetuximab response in 
head and neck cancer patients.
Kaplan-Meier plots of overall survival of 59 head and neck cancer cases after cetuximab 
treatment with low or high m
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Figure 53. Clonogenic assay of SKCO1 cells
Clonogenic assay of SKCO1 cells expressing control vector, PRMT1 shRNA or re
expressing shRNA resistant PRMT1 under cetuximab treatment (N = 5). 
expressed as mean ±SD. 
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CHAPTER 4. DISCUSSION  
4.1 Conclusion and significance 
Mutant KRAS is a widely recognized predictive marker for poor cetuximab 
response in colorectal cancer due to its association with poor patient survival. However, 
increasing evidence indicates that wild-type KRAS is insufficient to confer sensitivity to 
cetuximab and that some patients with mutant KRAS are still sensitive to cetuximab. 
Therefore, further investigation is warranted to elucidate the underlying mechanism of 
cetuximab resistance and identify other predictors of cetuximab response. Our data 
demonstrate that methylation of EGFR upregulates EGFR signaling, enhances 
tumorigenesis, and reduces cellular response to cetuximab. Patients with higher EGFR 
methylation level have higher recurrence rate after cetuximab treatment. Thus, 
methylated EGFR may serve as a biomarker to stratify colorectal cancer patients with the 
maximum benefit of cetuximab therapy. 
4.2 EGFR target therapy and predictive markers for drug resistance 
EGFR-targeted monoclonal antibodies have expanded the treatment options for 
colorectal cancer patients. Although these agents have great potential for individualized 
therapy, the reasons why some patients respond to treatment while others do not remain 
unclear. In this study, we demonstrate that PRMT1-mediated methylation of R198/200 on 
the extracellular domain of EGFR enhances receptor dimerization, EGFR signaling 
activation, cell proliferation, and reduces cellular response to cetuximab. Interestingly, 
although some studies have shown that mutant KRAS strongly represses EGF-stimulated 
activation of ERK phosphorylation in HCT116 and DLD1 colorectal cancer cell lines 
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(99), our data demonstrated that ERK was still activated by EGF stimulation in GEO 
(G12A) and SKCO1 (G12V) KRAS mutant cell lines (Fig. 17-21). The contradictory 
effect of EGF on ERK activation is somewhat expected as different cancer cell lines can 
behave differently. Moreover, knockdown of PRMT1 sensitized cells to cetuximab 
treatment regardless of KRAS mutation status (Fig. 43-45 and Fig. 53). High EGFR 
R198/200 methylation level correlated with higher recurrence rate in cetuximab treated 
patients, implying that EGFR R198/200 methylation has the potential to serve as a 
predictive marker for cetuximab resistance in clinical colorectal cancer therapy. It is 
worthwhile to mention that colorectal cancer patients carrying R497 polymorphism on 
EGFR extracellular domain 4 exhibit more unfavorable response to cetuximab than those 
carrying K497 (100). Although we also observed endogenous EGFR R497 methylation 
from mass spectrum analysis (Fig. 5), suggesting that this arginine methylation event may 
be another factor that contributes to cetuximab resistance, PRMT1 is not the 
methyltransferase for R497 methylation (D4), at least from our in vitro methylation assay 
(Fig. 7). Thus, identification of the PRMT that is responsible for R497 methylation would 
be critical to address this issue in the future. 
EGFR is a key regulator of proliferation and progression in human cancers. Five 
EGFR inhibitors, two monoclonal antibodies and three TKIs, have gained FDA approval 
on treatment of several cancer types (cetuximab for mCRC and head and neck cancer; 
panitumumab for mCRC; erlotinib for pancreatic cancer; gefitinib for non-small-cell lung 
cancer; and lapatinib for breast cancer) (101). Interestingly, it has been shown that 
EGFR-negative colon tumours have the potential to respond to cetuximab therapies (102). 
EGFR target therapeutic strategies show tumor regressions in approximately 10–20% of 
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advanced cancer patients. However, many tumors eventually acquire resistance to therapy. 
A high-throughput screening study showed that cetuximab-resistant non-small-cell lung 
cancer cells manifested strong activation of HER2, HER3 and cMET. Additionally, 
HER2 signaling could mediate resistance to tyrosine kinase inhibitors in breast cancer 
cell lines owing to the activation of alternative EGFR family receptors (103). In 
accordance, EGFR promotes dimerization and elevated activation of HER2 in cells, 
which acquire cetuximab resistance, with consequent activation of downstream cascades 
and sustained proliferation (104). Based on these studies, we performed IP-western to 
examine the interaction between Her-2 and wild type EGFR in comparison with the 
binding with R198/200K EGFR. The result showed that wild type EGFR has increased 
interaction with Her-2 upon EGF stimulation, while abolishing R198/200 methylation by 
mutations of R198/200K significantly reduced its binding to Her-2 (Fig. 56). In line with 
other reports, the stronger interaction between methylated EGFR and Her-2 may 
contribute to one of the mechanisms of EGFR methylation-induced cetuximab resistance. 
In addition, it has been reported that acquired resistance to cetuximab is accompanied by 
dysregulation of EGFR-Her-2 heterodimer internalization/degradation and prolonged 
signal transduction (104, 105), suggesting the EGFR methylation may contribute to 
cetuximab resistance at least partially through enhancing EGFR-Her-2 heterodimer. 
 
  
  
Figure 54. Co-immunoprecipitation of EGFR and He
type or R198/200K mutant EGFR.
 
                         
 
 
 
96 
r2 in cells overexpressing wild 
 
 
 
  
97 
 
4.3 Cross talk between PRMT family members 
We previously reported methylation on EGFR intracellular domain mediated by 
PRMT5 inhibits downstream ERK activation in breast cancer cells (53). Here, 
methylations on EGFR extracellular domain regulated by PRMT1 enhance receptor 
function in colorectal cancer cells. Interestingly, in colorectal cancer patients, elevated 
level of PRMT5 was observed and coincided with poor prognosis (106). A molecular 
switch that governs the tumor suppressive or oncogenic activities of different PRMTs and 
their downstream target proteins in different cancer types remains to be further 
investigated.   
It is known that some PRMTs may replace the role of another PRMT under some 
conditions, i.e. when the expression level of the major enzyme is low. We used in vitro 
methylation to know whether PRMT5, which also interacted with EGFR, could methylate 
R198/200, the screening analysis of PRMT1-8 showed only PRMT1 can methylate 
extracellular domain 2 R198/200 but not PRMT2-8, suggesting the particular methylation 
event of R198/200 may not be catalyzed by other PRMTs.  
4.4 Extracellular methylation of membrane receptors and their target therapies 
Several arginine methylated RTKs, such as EGFR and VEGFR-2, have been 
reported (53, 107). The current study demonstrates that arginine methylation on EGFR 
extracellular domain affects ligand-mediated signaling and may contribute to cetuximab 
resistance. Since many cell surface RTKs, including EGFR, HER2, and MET, are 
therapeutic targets and monoclonal antibodies against the extracellular domain of these 
RTKs are being used for therapy, this raises an interesting possibility that arginine 
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methylation of this region on other RTK may also play a role in the regulation of their 
activities and in response to their corresponding monoclonal antibody therapeutics.   
4.5 Locations where extracellular domain modification takes place 
Our results indicated that PRMT1 methylates EGFR before it reaches the cell 
membrane. However, the subcellular compartment in which PRMT1-mediated EGFR 
extracellular domain methylation occurs is interesting and remains unclear. Translation of 
type I transmembrane proteins, such as EGFR, begins on free ribosomes in the cytosol 
(108, 109). The nascent polypeptide chain, which includes the N-terminal signal 
sequence and extracellular domain, exposed to the cytosol during translation.  Subsequent 
recognition of the signal sequence within the nascent polypeptide chain by the signal 
recognition particle (SRP) recruits the ribosome-nascent polypeptide chain complex to 
the Sec61 translocon complex on the ER membrane, leading to insertion of the nascent 
polypeptide into the ER lumen (108, 109). Thus, there are at least two possibilities 
regarding where methylation may occur. First, EGFR R198/200 may be methylated by 
cytosolic PRMT1. EGFR R198/200 may be exposed to the cytosol and methylated by 
PRMT1 in the cytosol before the free ribosome-nascent polypeptide chain complex is 
recruited to ER or before the nascent polypeptide is inserted into ER lumen. Second, 
EGFR may be methylated by PRMT1 in the ER since the presence of PRMT1 and SAM 
in the ER has been reported (110, 111), and EGFR and PRMT1 were both detected in the 
isolated ER (Fig. 14). A systematic approach would be required to further address this 
interesting mechanism in the future. 
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PRMT family members are constitutively active, and there is only little evidence 
showing that methylation event occurs specifically under specific cellular conditions such 
as the cell cycle or response to extracellular stimuli (112, 113). Therefore, most known 
PRMT substrates are methylated at any given time, and it is unlikely that methylation 
carries out a signal transduction like protein phosphorylation. Consistent with these 
reports, EGFR extracellular domain R198/200 methylation by PRMT1 cannot be 
regulated by EGF stimulation as shown in Fig. 42. This suggests that PRMT1 may 
predispose newly synthesized EGFR molecules to adopt the active EGF-binding 
conformation at the cell surface. 
4.6 Future direction 
Overall, the role of PRMT1-mediated EGFR methylation in colorectal cancer 
tumorigenesis and its correlation with poorer patient outcomes and cetuximab response 
by affecting the EGF-EGFR binding affinity and subsequent signaling activation, as 
demonstrated here, provide an insight into the response to EGFR-targeted therapy and 
also open an avenue toward the understanding of how arginine methylation regulates the 
function of RTKs.  
The sub-cellular compartments where PRMT family members locate have not 
been well characterized yet. Interestingly, our study found that PRMT1 could be isolated 
with ER fraction. It is known that soluble endoplasmic reticulum (ER)–resident proteins 
usually contain a C-terminal KDEL-like motif, which prevents secretion of these ER 
resident proteins. Interaction between KDEL-like motifs of ER proteins with KDEL 
receptors, which localize in the intermediate compartment and Golgi apparatus, trigger 
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retrieval of ER resident proteins back to the ER via a coat protein I–dependent pathway 
(114). So far, three human KDEL receptors have been identified and each of them has a 
unique pattern of motifs with which it interacts, suggesting the specificity in the retrieval 
of human proteins that contain different KDEL variants. Intriguingly, a putative KDEL-
like motif (KVEDL) was found in C-terminus of PRMT1. This KVEDL sequence is not 
conserved between PRMT family members, implying a unique function of PRMT1. 
Examining the localization of PRMT1 with mutations on KVEDL motif would be 
interesting to confirm whether PRMT1 indeed localizes and retains in ER compartment 
through ER retention motif.  ER is a critical sub-cellular compartment where membrane 
receptors are synthesized and subsequently transported to the cell membrane. Identifying 
the ER-resident PRMT or extracellular domain modification enzymes would open an 
avenue regarding how intracellular proteins regulate cellular response to signals from 
extracellular challenges, such as tumor-targeting immune systems or tumor 
microenvironments.  
Although PRMT family members are constitutively active (112, 113), based on 
our calculation of the percentage of methylated EGFR in cells, only around 10 % of total 
EGFR are methylated (Fig. 57). In line with the report showing that ERα methylation is a 
dynamic process, which is methylated by PRMT1 and demethylated by arginine 
demethylase, JMJD6 (81, 115); global proteomic analysis also showed that 
arginine methylation sites in human cells are regulated dynamically by unknown arginine 
demethylase during transcriptional arrest (116). It is possible that arginine demethylation 
process is a general event regulating cellular arginine methylation level. So far, JMJD6 is 
the only known arginine demethylase and its demethylation activity has been debated for 
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a long time (81, 117-119). Since our study showed that high methylation level of EGFR 
R198/200 correlates with poor patient outcome, identifying the corresponding arginine 
demethylase and understanding the regulation between protein arginine methylation and 
demethylation would significantly broaden our knowledge about the field of arginine 
methylation and may guide the therapeutic strategy in the future. 
  
  
Figure 55. Methylation percentage of endogenous EGFR from SKCO1 cell.
A, EGFR antibody was used 
Then, dot blot was performed 
CRUZ BIOTECHNOLOGY, INC., EGFR (1005): sc
immunoblotting by total EGFR antibody to calculate the amount of EGFR protein
dilution). B, R198/200 methylated peptide 
was performed by me-R198/200 antibody to calculate amount of methylated EGFR 
protein. The result indicated there is around 
EGFR from SKCO1 cells were methylated
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10.5 % (18.8/(2x 89.4)) of endogenous 
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